Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
19 Julho 2024 - 1:00PM
UK Regulatory
Information on the Total Number of Voting Rights (Denominator)
following Conversion Notice from Atlas
Information on the Total Number of Voting
Rights (Denominator) following Conversion Notice from
Atlas
Atlas Special Opportunities, LLC has
converted 4 convertible bonds in Oxurion resulting in a EUR 100,000
capital increase. This is part of Atlas Special Opportunities,
LLC’s EUR 20 million Capital Commitment1 that
will allow Oxurion to focus on developing innovative therapeutics
to preserve the vision of elderly people, targeting potential
market opportunities of USD 3-6 billion.
Leuven, BELGIUM – 19 July, 2024 – 06:00
PM CET – In accordance with article 15 of the Belgian Act
of May 2, 2007 on the disclosure of major participations in issuers
of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, Oxurion NV (Euronext Brussels:
OXUR) (the “Company” or “Oxurion”), announces the below
information, following the issuance of 1,086,956,521 new ordinary
shares on July 18, 2024, for a total amount of EUR 100,000 pursuant
to the Capital Commitment entered into with Atlas Special
Opportunities, LLC.
Following completion of capital increase through
the conversion of the convertible bonds, the total number of shares
issued by Oxurion amounts to 13,362,647,372 outstanding ordinary
shares carrying voting rights (compared to 12,275,690,851
outstanding ordinary shares previously). This number will be used
as the denominator for the calculation of the percentages of
shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
|
84,756,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
13,362,647,372 |
- Total number of ordinary shares (=
denominator)
|
13,362,647,372 |
- Number of outstanding, granted
rights to subscribe to securities carrying voting rights not yet
issued (excluding any shares resulting (a) from the potential
conversion of any convertibles bonds issued on December 20, 2021 to
the benefit of Kreos Capital VI (UK) Limited, Pontifax Medison
Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. or
(b) from the exercise of any subscription rights issued by the
Company to the benefits of employees, consultants or directors of
the Company (as they are both currently significantly
out-of-the-money):
|
|
- 342 convertible bonds issued on
March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August
10, 2023, September 15, 2023, October 20, 2023, October 24, 2023,
November 15, 2023 and November 15, 2023, January 9, 2024, February
2, 2024, March 4, 2024, April 10, 2024, May 22, 2024, June 5, 2024
and July 12, 2024, entitling its holder, Atlas Special
Opportunities, LLC, to subscribe to a total number of securities
carrying voting rights (all ordinary shares) in accordance with the
terms and conditions of these convertible bonds pursuant to the
Subscription Agreement entered into between the Company and Atlas
Special Opportunities, LLC on March 1, 2023, as amended on
September 10, 2023 and December 22, 2023.
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may
be considered “forward-looking”. Such forward-looking statements
are based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
Please contact for additional information:
Oxurion NV
Pascal Ghoson
Chief Executive Officer
pascal.ghoson@oxurion.com
|
1 Press release Oxurion, 02/03/2023
Oxurion NV (EU:OXUR)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Oxurion NV (EU:OXUR)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
